Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge.

Literature DB >> 26957887

The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge.

Abstract

What started as a trickle of new agents that help the body's immune system fight cancer has now become a flood, despite some daunting adverse effects. This report discusses the new drugs, indications, and combinations that continue to emerge.

Entities: Disease

Year: 2016 PMID： 26957887 PMCID： PMC4771089

Source DB: PubMed Journal: P T ISSN： 1052-1372

8 in total

1. Nivolumab in previously untreated melanoma without BRAF mutation.

Authors: Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245

2. OX40 is a potent immune-stimulating target in late-stage cancer patients.

Authors: Brendan D Curti; Magdalena Kovacsovics-Bankowski; Nicholas Morris; Edwin Walker; Lana Chisholm; Kevin Floyd; Joshua Walker; Iliana Gonzalez; Tanisha Meeuwsen; Bernard A Fox; Tarsem Moudgil; William Miller; Daniel Haley; Todd Coffey; Brenda Fisher; Laurie Delanty-Miller; Nicole Rymarchyk; Tracy Kelly; Todd Crocenzi; Eric Bernstein; Rachel Sanborn; Walter J Urba; Andrew D Weinberg
Journal: Cancer Res Date: 2013-10-31 Impact factor: 12.701

3. Improved survival with ipilimumab in patients with metastatic melanoma.

Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245

4. Society for melanoma research and american heart association scientific sessions.

Authors: Walter Alexander
Journal: P T Date: 2015-01

Review 5. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.

Authors: Mabel Ryder; Margaret Callahan; Michael A Postow; Jedd Wolchok; James A Fagin
Journal: Endocr Relat Cancer Date: 2014-03-07 Impact factor: 5.678

6. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors: Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal: Lancet Date: 2015-12-19 Impact factor: 79.321

7. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors: Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal: N Engl J Med Date: 2014-12-06 Impact factor: 91.245

8. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors: Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal: Lancet Date: 2014-07-15 Impact factor: 79.321

8 in total

35 in total

1. Metallic Nanoparticles for Cancer Immunotherapy.

Authors: Emily Reiser Evans; Pallavi Bugga; Vishwaratn Asthana; Rebekah Drezek
Journal: Mater Today (Kidlington) Date: 2017-12-14 Impact factor: 31.041

Review 2. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy.

Authors: Jung-Mao Hsu; Chia-Wei Li; Yun-Ju Lai; Mien-Chie Hung
Journal: Cancer Res Date: 2018-11-15 Impact factor: 12.701

Review 3. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.

Authors: Thomas Powles; Andrea Necchi; Galit Rosen; Subramanian Hariharan; Andrea B Apolo
Journal: Clin Genitourin Cancer Date: 2017-12-06 Impact factor: 2.872

4. The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.

Authors: Emily Z Keung; Esosa U Ukponmwan; Alexandria P Cogdill; Jennifer A Wargo
Journal: Ann Surg Oncol Date: 2018-03-02 Impact factor: 5.344

Review 5. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers.

Authors: Akshay Sood; Daniel Cole; Firas Abdollah; Ben Eilender; Zade Roumayah; Mustafa Deebajah; Ali Dabaja; Shaheen Alanee
Journal: Curr Urol Rep Date: 2018-07-03 Impact factor: 3.092

6. Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review.

Authors: Ammar Haikal; E Borba; Taqui Khaja; Gary Doolittle; Paul Schmidt
Journal: Avicenna J Med Date: 2018 Jan-Mar

Review 10. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors: Ping-Pin Zheng; Jin Li; Johan M Kros
Journal: Med Res Rev Date: 2017-09-01 Impact factor: 12.944